The US Food and Drug Administration (FDA) announced that new research shows an increased risk of pancreatic cancer in diabetic patients treated with a class of drugs called incretin mimetics. These findings were based on FDA research on pancreatic tissues taken from diabetic patients that took incretin mimetics and died for unknown reasons. Drugs in the incretin mimetic class include: Exenatide (Byetta, Bydureon) Liraglutide (Victoza) Sitagliptin (Januvia) These drugs work by imitating incretin hormones that the body normally produces to rouse the release of insulin after eating a meal. Incretin mimetics are used along with diet and exercise to lower blood sugar in those with Type 2 diabetes. This research was executed to inform the public that the FDA intends on investigating these new findings. The FDA will release its final conclusions about incretin mimetics when the research is finalized. What to Do if You Have Taken a Dangerous or…
Read More »
-
Let Us Review Your Case
-
Recent Posts
Categories
Archives
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- January 2011
- October 2010